Compare SPCB & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | XLO |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | SPCB | XLO |
|---|---|---|
| Price | $9.25 | $0.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $2.00 |
| AVG Volume (30 Days) | 104.4K | ★ 798.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | $26,739,000.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $519.70 |
| Revenue Next Year | $29.31 | $44.57 |
| P/E Ratio | $11.03 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $3.08 | $0.62 |
| 52 Week High | $18.95 | $1.70 |
| Indicator | SPCB | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 46.74 |
| Support Level | $7.98 | $0.73 |
| Resistance Level | $9.49 | $0.76 |
| Average True Range (ATR) | 0.80 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 46.95 | 54.21 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.